Several second- and third-generation ALK inhibitors have also shown either established or promising clinical activity for ALK-positive NSCLC patients who progressed on crizotinib, supporting the development of potent ALK inhibitors as an effective strategy to overcome resistance to crizotinib [17]. This evidence concerns the gene ALK and non-small cell lung carcinoma.